Acceder

Novavax (NVAX): Un Nuevo Comienzo

33,6K respuestas
Novavax (NVAX): Un Nuevo Comienzo
82 suscriptores
Novavax (NVAX): Un Nuevo Comienzo
Página
342 / 2.282
#5116

Re: Novavax (NVAX): Un Nuevo Comienzo

Y simplemente tan solo con lo que se sabe de la f3 materna  es motivo para pasar de un target de 2 a 10.?  Podrían saber algo más o es solo  un numero para manipular el precio?

 

 

 

 

 

#5118

Re: Novavax (NVAX): Un Nuevo Comienzo

Me gusta el comentario, corto, conciso y en línea con lo que pienso.

Paciencia.
Es difícil tenerla, pero trae muy buenos resultados.....

#5119

Re: Novavax (NVAX): Un Nuevo Comienzo

Vamos y el tuyo para estar con el móvil de nota, si llegas a estar en tu ordenador aún sigo leyendo al cierre del mercado 😂😜 Eso sí, yo me he hecho más radical en mi teoría, manipulación total, subida hasta zona de 8$ en un plazo de tiempo relativamente corto, gráfica mensual, y nuevamente haciendo el agosto los que están como sanguijuelas en el valor, ya dije, los motivos serán los que sean, una posible pandemia gripe aviar, una vacuna VLP gripe cuadriivalente, una supernanotecnologia vacuna RSV, ebola, Nanoflu, etc, etc, da igual, ahí están las subidas y bajadas en mensual de este carrusel en el que algunos van muy cómodos montados.

Paciencia.
Es difícil tenerla, pero trae muy buenos resultados.....

#5121

Re: Novavax (NVAX): Un Nuevo Comienzo

Pues yo veo el pre en rojo! -3%

#5123

Re: Novavax (NVAX): Un Nuevo Comienzo

Esperábamos un gap up y va aser down!!!!!
-7%

#5124

Re: Novavax (NVAX): Un Nuevo Comienzo

otro upgrade

Ladenburg Thalmann analyst Kevin DeGeeter raised his price target for Novavax to $2.50 after the company additional details of its informational analysis from the ongoing Phase III study of its RSV nanoparticle vaccine in a maternal population. 40% protection is a "meaningful benchmark" for both business development discussions and interaction with regulators, the analyst tells investors in a research note. He points out that an analysis of the first 1,307 patients suggested a vaccine efficacy of between 45% and 100%. DeGeeter reiterates a Buy rating on Novavax.

Read more at:
https://thefly.com/landingPageNews.php?id=2665784
Ladenburg Thalmann analyst Kevin DeGeeter raised his price target for Novavax to $2.50 after the company additional details of its informational analysis from the ongoing Phase III study of its RSV nanoparticle vaccine in a maternal population. 40% protection is a "meaningful benchmark" for both business development discussions and interaction with regulators, the analyst tells investors in a research note. He points out that an analysis of the first 1,307 patients suggested a vaccine efficacy of between 45% and 100%. DeGeeter reiterates a Buy rating on Novavax.

Read more at:
https://thefly.com/landingPageNews.php?id=2665784

PT raised to $2.50 from $1.60 at Ladenburg

Ladenburg Thalmann analyst Kevin DeGeeter raised his price target for Novavax to $2.50 after the company additional details of its informational analysis from the ongoing Phase III study of its RSV nanoparticle vaccine in a maternal population. 40% protection is a "meaningful benchmark" for both business development discussions and interaction with regulators, the analyst tells investors in a research note. He points out that an analysis of the first 1,307 patients suggested a vaccine efficacy of between 45% and 100%. DeGeeter reiterates a Buy rating on Novavax.

Ladenburg Thalmann analyst Kevin DeGeeter raised his price target for Novavax to $2.50 after the company additional details of its informational analysis from the ongoing Phase III study of its RSV nanoparticle vaccine in a maternal population. 40% protection is a "meaningful benchmark" for both business development discussions and interaction with regulators, the analyst tells investors in a research note. He points out that an analysis of the first 1,307 patients suggested a vaccine efficacy of between 45% and 100%. DeGeeter reiterates a Buy rating on Novavax.

Read more at:
https://thefly.com/landingPageNews.php?id=2665784
Ladenburg Thalmann analyst Kevin DeGeeter raised his price target for Novavax to $2.50 after the company additional details of its informational analysis from the ongoing Phase III study of its RSV nanoparticle vaccine in a maternal population. 40% protection is a "meaningful benchmark" for both business development discussions and interaction with regulators, the analyst tells investors in a research note. He points out that an analysis of the first 1,307 patients suggested a vaccine efficacy of between 45% and 100%. DeGeeter reiterates a Buy rating on Novavax.

Read more at:
https://thefly.com/landingPageNews.php?id=2665784
Ladenburg Thalmann analyst Kevin DeGeeter raised his price target for Novavax to $2.50 after the company additional details of its informational analysis from the ongoing Phase III study of its RSV nanoparticle vaccine in a maternal population. 40% protection is a "meaningful benchmark" for both business development discussions and interaction with regulators, the analyst tells investors in a research note. He points out that an analysis of the first 1,307 patients suggested a vaccine efficacy of between 45% and 100%. DeGeeter reiterates a Buy rating on Novavax.

Read more at:
https://thefly.com/landingPageNews.php?id=2665784
Ladenburg Thalmann analyst Kevin DeGeeter raised his price target for Novavax to $2.50 after the company additional details of its informational analysis from the ongoing Phase III study of its RSV nanoparticle vaccine in a maternal population. 40% protection is a "meaningful benchmark" for both business development discussions and interaction with regulators, the analyst tells investors in a research note. He points out that an analysis of the first 1,307 patients suggested a vaccine efficacy of between 45% and 100%. DeGeeter reiterates a Buy rating on Novavax.

Read more at:
https://thefly.com/landingPageNews.php?id=2665784
Ladenburg Thalmann analyst Kevin DeGeeter raised his price target for Novavax to $2.50 after the company additional details of its informational analysis from the ongoing Phase III study of its RSV nanoparticle vaccine in a maternal population. 40% protection is a "meaningful benchmark" for both business development discussions and interaction with regulators, the analyst tells investors in a research note. He points out that an analysis of the first 1,307 patients suggested a vaccine efficacy of between 45% and 100%. DeGeeter reiterates a Buy rating on Novavax.

Read more at:
https://thefly.com/landingPageNews.php?id=2665784
Ladenburg Thalmann analyst Kevin DeGeeter raised his price target for Novavax to $2.50 after the company additional details of its informational analysis from the ongoing Phase III study of its RSV nanoparticle vaccine in a maternal population. 40% protection is a "meaningful benchmark" for both business development discussions and interaction with regulators, the analyst tells investors in a research note. He points out that an analysis of the first 1,307 patients suggested a vaccine efficacy of between 45% and 100%. DeGeeter reiterates a Buy rating on Novavax.

Read more at:
https://thefly.com/landingPageNews.php?id=2665784
Ladenburg Thalmann analyst Kevin DeGeeter raised his price target for Novavax to $2.50 after the company additional details of its informational analysis from the ongoing Phase III study of its RSV nanoparticle vaccine in a maternal population. 40% protection is a "meaningful benchmark" for both business development discussions and interaction with regulators, the analyst tells investors in a research note. He points out that an analysis of the first 1,307 patients suggested a vaccine efficacy of between 45% and 100%. DeGeeter reiterates a Buy rating on Novavax.

Read more at:
https://thefly.com/landingPageNews.php?id=2665784
Ladenburg Thalmann analyst Kevin DeGeeter raised his price target for Novavax to $2.50 after the company additional details of its informational analysis from the ongoing Phase III study of its RSV nanoparticle vaccine in a maternal population. 40% protection is a "meaningful benchmark" for both business development discussions and interaction with regulators, the analyst tells investors in a research note. He points out that an analysis of the first 1,307 patients suggested a vaccine efficacy of between 45% and 100%. DeGeeter reiterates a Buy rating on Novavax.

Read more at:
https://thefly.com/landingPageNews.php?id=2665784
Ladenburg Thalmann analyst Kevin DeGeeter raised his price target for Novavax to $2.50 after the company additional details of its informational analysis from the ongoing Phase III study of its RSV nanoparticle vaccine in a maternal population. 40% protection is a "meaningful benchmark" for both business development discussions and interaction with regulators, the analyst tells investors in a research note. He points out that an analysis of the first 1,307 patients suggested a vaccine efficacy of between 45% and 100%. DeGeeter reiterates a Buy rating on Novavax.

Read more at:
https://thefly.com/landingPageNews.php?id=2665784

 

 
 
 
 
 
#5125

Re: Novavax (NVAX): Un Nuevo Comienzo

Pues ayer empezamos en rojo y terminamos en muy verde. Veremos, aunque apunta al rojo. 

#5126

Re: Novavax (NVAX): Un Nuevo Comienzo

No me desencaja que pase algo asi, no se si hasta 8 pero....si quiza hasta 4-5- Ahora se supone que coge la curva euforica positiva y con temitas como nano,que si comentario de negociaciones con partner etc etc etc....

Pero bueno, como decis con esta bicha, tb puede ser que casquen un -30% si no es hoy mañana para pillar a todos de inocentillos.

Yo personalmente no estoy agusto dentro,y si el dia de mañana tengo la suerte de volver a donde estaba, lo utilizare de aprendizaje de doctorado en bolsa que es el del CONTROLAR LAS EMOCIONES.

#5127

Re: Novavax (NVAX): Un Nuevo Comienzo

Alguien ha pensado que tras la subidita inicial los tibus pillados a 8 desde septiembre 2016 estén comprando para promediar?
Si esto es así como están tan arriba tienen que comprar muchas para rebajar la media, esto se produciría con gran volumen y subida vertical y concluiría cuando ya ganen pasta, soltadas del mismo calibre y para abajo

Es solo una hipótesis a lo sucedido ayer y lo que nos espera

Lo fácil es culpar a otros o a la mala suerte... en vez de al poco cuidado

#5128

Re: Novavax (NVAX): Un Nuevo Comienzo

Una consulta. ¿Cómo hacéis para vender un paquete grande (pongamos 50K) asegurando que lo vendéis todo y que el precio no se va muy abajo?

Lo digo porque ayer estuve a punto de vender las 30K que tengo y no sabía muy bien como plantearlo. En el mercado español utilizo dos herramientas: el tiempo real y la profundidad de mercado. Si veo que hay suficiente volumen de compra entre las líneas 1 y 5, lanzo la orden limitada al precio de la línea 5 y me aseguro vender todo el paquete y a un precio mínimo.

Pero en el Nasdaq, el tiempo real que me ofrece mi broker lleva casi un minuto de retraso y, en jornadas como las de ayer, el precio a veces da bandazos en menos de un minuto, así que si lanzo la orden voy un poco a ciegas. El tiempo real real lo veo en una web pero allí no me ofrece profundidad.

¿Cómo hacéis? ¿Ponéis todo el paquete de golpe a un precio limitado? ¿o fraccionáis la venta en paquetes pequeños?

#5129

Re: Novavax (NVAX): Un Nuevo Comienzo

cambia de broker....

#5130

Re: Novavax (NVAX): Un Nuevo Comienzo

Opero con Selfbank y estoy "menos descontento" que con otros broker que había probado antes. Les he llamado y me dicen que el desfase en el tiempo real debía ser una anomalía y que si me vuelve a pasar les llame. Pero, en cualquier caso no tienen disponible la profundidad para el Nasdaq.

¿Sabéis que brokers la ofrecen? Gracias

Te puede interesar...
  1. Inflación y tipos en el punto de mira, la historia no se repite pero rima
  2. La Euforia Post-Trump: ¿Calma o Tormenta en el Mercado?